These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 37735924

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Children versus adults: pharmacokinetic and adverse-effect differences.
    Anderson GD.
    Epilepsia; 2002; 43 Suppl 3():53-9. PubMed ID: 12060006
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.
    Amini-Shirazi N, Ghahremani MH, Ahmadkhaniha R, Mandegary A, Dadgar A, Abdollahi M, Shadnia S, Pakdaman H, Kebriaeezadeh A.
    Toxicol Mech Methods; 2010 Oct; 20(8):452-7. PubMed ID: 20602621
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
    Levy RH, Rettenmeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, Acheampong A, Tor J, Guyot M, Loiseau P.
    Clin Pharmacol Ther; 1990 Sep; 48(3):225-35. PubMed ID: 2119269
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.
    Conner TM, Nikolian VC, Georgoff PE, Pai MP, Alam HB, Sun D, Reed RC, Zhang T.
    Eur J Pharm Sci; 2018 Jan 01; 111():465-481. PubMed ID: 29030176
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X, Li X, Zhang T, Zhao L.
    Basic Clin Pharmacol Toxicol; 2018 Nov 01; 123(5):628-634. PubMed ID: 29791065
    [Abstract] [Full Text] [Related]

  • 13. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H, Nau H, Schultze K, Wittfoht W, Drews E, Penzien J, Seidel U.
    Epilepsia; 1993 Nov 01; 34(2):332-46. PubMed ID: 8453944
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of Age and Genotype on Serum Concentrations of Valproic Acid and Its Hepatotoxic Metabolites in Chinese Pediatric Patients With Epilepsy.
    Zhao M, Chen Y, Wang M, Li G, Zhao L.
    Ther Drug Monit; 2020 Oct 01; 42(5):760-765. PubMed ID: 32107351
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ, Wang XD, Wang HS, Chen SD, Zhou LM, Li JL, Shu WY, Zhou JQ, Fang ZY, Zhang Y, Huang M.
    Seizure; 2012 Mar 01; 21(2):110-7. PubMed ID: 22055352
    [Abstract] [Full Text] [Related]

  • 18. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
    Lee MS, Lee YJ, Kim BJ, Shin KJ, Chung BC, Baek DJ, Jung BH.
    Arch Pharm Res; 2009 Jul 01; 32(7):1029-35. PubMed ID: 19641884
    [Abstract] [Full Text] [Related]

  • 19. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
    Tang W, Abbott FS.
    Drug Metab Dispos; 1997 Feb 01; 25(2):219-27. PubMed ID: 9029053
    [Abstract] [Full Text] [Related]

  • 20. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
    Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K.
    Ther Drug Monit; 2014 Jun 01; 36(3):406-9. PubMed ID: 24365988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.